Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3023% above fair value
$443.89−14.04 (-3.07%)
Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%
Amgen operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Amgen's operating cash flow for the twelve months ending Sep 30, 2026 was $12.04B, down 8.3% year over year. For fiscal 2025 it was $9.96B, down 13.3% from the year before. Over ten years it grew 0.2% a year on average. The highest annual figure on record is $11.49B in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.96B | -13.3% |
| FY2024 | Dec 31, 2024 | $11.49B | +35.6% |
| FY2023 | Dec 31, 2023 | $8.47B | -12.9% |
| FY2022 | Dec 31, 2022 | $9.72B | +5.0% |
| FY2021 | Dec 31, 2021 | $9.26B | -11.8% |
| FY2020 | Dec 31, 2020 | $10.50B | +14.7% |
| FY2019 | Dec 31, 2019 | $9.15B | -19.0% |
| FY2018 | Dec 31, 2018 | $11.30B | +1.1% |
| FY2017 | Dec 31, 2017 | $11.18B | +7.9% |
| FY2016 | Dec 31, 2016 | $10.35B | +6.4% |
| FY2015 | Dec 31, 2015 | $9.73B | +8.7% |
| FY2014 | Dec 31, 2014 | $8.95B | +42.3% |
| FY2013 | Dec 31, 2013 | $6.29B | +7.0% |
| FY2012 | Dec 31, 2012 | $5.88B | +14.9% |
| FY2011 | Dec 31, 2011 | $5.12B | -11.5% |
| FY2010 | Dec 31, 2010 | $5.79B | -8.7% |
| FY2009 | Dec 31, 2009 | $6.34B | +5.8% |
| FY2008 | Dec 31, 2008 | $5.99B | +10.9% |
| FY2007 | Dec 31, 2007 | $5.40B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.24B | -9.5% |
| Q2 FY2026 | Jun 30, 2026 | $4.00B | +75.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.19B | +57.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.60B | -66.4% |
| Q3 FY2025 | Sep 30, 2025 | $4.68B | +31.2% |
| Q2 FY2025 | Jun 30, 2025 | $2.28B | -7.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.39B | +101.9% |
| Q4 FY2024 | Dec 31, 2024 | $4.77B | +786.8% |
| Q3 FY2024 | Sep 30, 2024 | $3.57B | +29.4% |
| Q2 FY2024 | Jun 30, 2024 | $2.46B | -40.2% |
| Q1 FY2024 | Mar 31, 2024 | $689.00M | -35.2% |
| Q4 FY2023 | Dec 31, 2023 | $538.00M | -79.7% |
| Q3 FY2023 | Sep 30, 2023 | $2.76B | -7.3% |
| Q2 FY2023 | Jun 30, 2023 | $4.11B | +112.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.06B | -50.8% |
| Q4 FY2022 | Dec 31, 2022 | $2.65B | -5.7% |
| Q3 FY2022 | Sep 30, 2022 | $2.98B | +41.5% |
| Q2 FY2022 | Jun 30, 2022 | $1.93B | -10.4% |
| Q1 FY2022 | Mar 31, 2022 | $2.16B | -35.7% |
| Q4 FY2021 | Dec 31, 2021 | $2.81B | -1.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.10B | -1.4% |
| Q4 FY2020 | Dec 31, 2020 | $2.15B | +52.3% |
| Q3 FY2020 | Sep 30, 2020 | $3.37B | +82.5% |
| Q2 FY2020 | Jun 30, 2020 | $2.84B | -11.0% |
| Q1 FY2020 | Mar 31, 2020 | $2.13B | -34.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.41B | -32.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.85B | -32.3% |
| Q4 FY2018 | Dec 31, 2018 | $3.19B | +6.0% |
| Q3 FY2018 | Sep 30, 2018 | $3.27B | -5.2% |
| Q2 FY2018 | Jun 30, 2018 | $2.10B | -9.6% |
| Q1 FY2018 | Mar 31, 2018 | $2.73B | +14.3% |
| Q4 FY2017 | Dec 31, 2017 | $3.01B | -2.8% |
| Q3 FY2017 | Sep 30, 2017 | $3.45B | +29.8% |
| Q2 FY2017 | Jun 30, 2017 | $2.33B | -13.1% |
| Q1 FY2017 | Mar 31, 2017 | $2.39B | – |
| Q4 FY2016 | Dec 31, 2016 | $3.10B | – |
| Q3 FY2016 | Sep 30, 2016 | $2.66B | – |
| Q2 FY2016 | Jun 30, 2016 | $2.68B | – |
See a number that looks wrong?